FBLG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
FibroBiologics Inc (FBLG) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has weak financial performance, no significant trading trends, and lacks strong technical or proprietary trading signals. While there are some positive catalysts like clinical trial approvals and Nasdaq compliance extensions, the company's financial struggles and bearish moving averages make it a risky investment at this time.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral at 69.699, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 0.294, which may limit further short-term upside. Overall, the technical indicators do not strongly support a buy decision.
Approval to initiate a Phase 1/2 clinical trial for CYWC628 targeting diabetic foot ulcers.
Nasdaq compliance extension until February 27, 2026, allowing the company more time to meet listing requirements.
Raised $7.2 million to enhance its financial position.
Rising expenses led to a net loss of $18.6 million in 2025, up from $11.2 million in
EPS dropped by 44.44% YoY in Q4
No significant hedge fund or insider trading trends, indicating a lack of strong institutional or insider confidence.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $3.24 million (up 4.68% YoY), and a significant drop in EPS (-44.44% YoY). Gross margin remains at 0%. The financials indicate poor performance and limited growth potential.
H.C. Wainwright recently lowered the price target from $5 to $4 but maintained a Buy rating. This suggests cautious optimism but reflects reduced confidence in the stock's potential.
